RE: comparison30 Jun 2022 19:37
I think we mustn’t forget the bigger picture
The market is driven on sentiment rather than the longer term
We have a proven, revolutionary, peer reviewed product with the many advantages over the competition
It improves the prognosis, slashes costs and there are high barriers to entry such as the lengthy FDA approval
Andrew Newland needs to get Parsortix commercialised and this will take time. The labs are running and the certification process is far advanced but yet to fully complete
Big pharma is waking up to the opportunities Parsortix provides and i anticipate significant news flow in the coming half
Andrew Newland has commented that the institutional investors want the Angle team to continue to develop Parsortix rather than a buy out being the end game
It’s premature to suggest they would have a change of heart in just a few weeks after the FDA approval. But if progress was not forthcoming that might change Either way it’s win win for shareholders and at a quid a share they are a massive bargain given the value of what has been achieved so far